Oltipraz - PharmaKing

Drug Profile

Oltipraz - PharmaKing

Alternative Names: PMK-N01GI1

Latest Information Update: 22 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaKing
  • Class Chemoprotectants; Organic sulfur compounds; Pyrazines; Small molecules
  • Mechanism of Action Fatty acid inhibitors; Gene expression inhibitors; Glutathione transferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-alcoholic fatty liver disease

Most Recent Events

  • 22 Mar 2017 Phase-III development for Non-alcoholic fatty liver disease is ongoing in South Korea (PO)
  • 28 Feb 2014 Phase-III clinical trials in Non-alcoholic fatty liver disease in South Korea (PO)
  • 19 Feb 2014 PharmaKing plans a phase III trial for Non-alcoholic fatty liver disease in South Korea (NCT02068339)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top